Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
about
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid raftsResistance to antiplatelet drugs: current status and future researchN-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceIncreased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.Bacitracin reveals a role for multiple thiol isomerases in platelet function.Pharmacochemistry of the platelet purinergic receptors.Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: implications for an activation microswitch region.Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors.Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of hemeClopidogrel: interactions with the P2Y12 receptor and clinical relevance.The disulfide isomerase ERp57 mediates platelet aggregation, hemostasis, and thrombosisAllele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patientsFormation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation.Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma?Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.Clopidogrel resistance--the cardiologist's perspective.Clopidogrel resistance: pharmacokinetic or pharmacogenetic?Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Pharmacogenetics guided anticoagulation.Pharmacokinetic basis of the antiplatelet action of prasugrel.P2Y12 receptor: platelet thrombus formation and medical interventions.Clopidogrel resistance: the way forward.Molecular defects of the platelet P2 receptors.The P2Y(12) receptor as a target of antithrombotic drugsThe contribution of zinc to platelet behaviour during haemostasis and thrombosis.The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms.Cangrelor for treatment during percutaneous coronary intervention.The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413.Interleukin-10 does not modulate clopidogrel platelet response in mice.Pharmacogenetic testing in population of South Ural.N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression.Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis.Determinants to optimize response to clopidogrel in acute coronary syndromeUnderstanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism
P2860
Q24675155-FF9EE268-6A73-41E0-A30C-8AF0F818662EQ28192298-AF4A73E3-E4AB-4E38-842B-BF04B55B4C50Q30497987-F5FB28D6-B68C-4904-9CB5-17337C24B92EQ30528247-1E54D74D-7302-4AAC-A485-6681DB8DE5C5Q30806590-D55D4831-BC8D-4A77-8D5D-121947E915A7Q33869922-A26D572F-F787-4C6D-A14C-1E49A98FCAE1Q34169728-6A41BA4A-DBF4-4746-BDA8-8B6721E49186Q34181416-9AA94404-ECD6-4FED-82D4-D5F20E25AADEQ34339780-9053E8D8-4158-4A31-A5A3-6443DFC8363DQ34455950-9EBD0F2A-8299-4F15-9F0B-743B8207083EQ35148953-85F508D1-1E91-4E89-9E66-257A54CBE099Q35176063-7521A9E0-BF67-4551-8996-AAF2FE9CAD72Q35415762-88590924-BAE3-421C-AEDB-33A1686E997DQ35605112-BBDBC2BC-06F4-4217-96E0-59421144BC84Q35776997-CBB9F6BE-E145-43F3-B9F1-D8DDC701ACCFQ35802686-1BE92A8C-2090-47B9-B405-80058C5589C8Q36105504-54E2A9CF-83E9-4B57-840B-C89DD599483BQ36201452-0A1D6AD7-C1E2-44AC-BAC9-B7007C2B3DD9Q36266153-217A7CC4-2B93-4C27-B357-13E033F88D69Q36407222-1B60C74E-C811-4FD4-BBC8-93EAB3FC9E53Q36717084-3F3EAA31-780D-4DE3-8B04-F67794625061Q36819608-6A03D640-15C2-4829-9386-2AA934C40A07Q37402214-99CDDCF5-0408-41DB-A01C-6005628ADEBAQ37693951-45FE2F51-0C30-4180-BF20-775E2B93187AQ37808224-910A7063-E7A3-46FB-8A4E-C0A3251B54A2Q37927151-567ABC35-63B9-46DE-AE11-496ED6EFFB26Q38051192-A1B198E1-2D8C-4243-9E22-E9024E400E34Q38274517-E6A53F61-F149-4F10-AD8F-DED9AE8756EFQ38306690-12585A5E-1C45-4EB5-AEC2-D317FF814699Q38306767-1D3BA252-7F1C-4AA5-BC37-A1A936AC6616Q38685836-CF8BF413-83BC-44C6-B9E7-CC2146DE52A1Q38756994-7AEA0281-75CC-4855-95EC-5E036BD86D74Q39204251-C925F480-FB03-40CE-AF31-3599533A38E7Q39297464-050BFFBE-5289-4AFF-A680-582D8F49E750Q40163750-A1BEE872-CED7-43E7-9EC9-526ABD22C65FQ40240189-738638BF-76EF-4264-9FA8-155416A46F5BQ40573764-C95FFFC1-9BD0-4C7F-BEF5-09A7FC066464Q41651465-F1574DB1-38B6-41B3-9F55-4986782D555DQ41848961-AC1A6C82-E464-49EA-B5D6-EF84F1BC9D39Q42425352-D51EC02D-E9CB-4CFB-B825-DE444F7268AB
P2860
Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@ast
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@en
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@nl
type
label
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@ast
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@en
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@nl
prefLabel
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@ast
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@en
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@nl
P2093
P1433
P1476
Inactivation of the human P2Y1 ...... ne residues, Cys17 and Cys270.
@en
P2093
Jianguo Jin
Robert T Dorsam
Satya P Kunapuli
Soochong Kim
Zhongren Ding
P304
P356
10.1182/BLOOD-2002-10-3027
P407
P577
2003-01-30T00:00:00Z